<DOC>
	<DOC>NCT02839473</DOC>
	<brief_summary>The primary objective consisted of avoiding deterioration and/or restoring the integrity of the skin of patients treated by radiotherapy, right from the first signs of grade 1 or 2 radiation dermatitis.</brief_summary>
	<brief_title>HydrosorbÂ® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Radiodermatitis</mesh_term>
	<criteria>Women treated by normo fractionated radiotherapy for breast cancer Presenting grade 1 or 2 radiation dermatitis during the treatment and who provided their written informed consent were included in the study. Exclusion criteria: Were male patients Radiation dermatitis already treated or caused by another treatment Subjects deprived of their freedom or under guardianship Subjects in whom medical followup was impossible A cancer wound or skin flap on the irradiated zone A history of allergic skin reaction Concomitant chemotherapy or concomitant bevacizumab therapy and bilateral irradiation.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>